Clinical Trial Update: First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

View source ↗

Summary

A Pfizer-sponsored real-world study is evaluating first-line palbociclib with endocrine therapy for HR+/HER2- advanced breast cancer; the trial is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Status: ACTIVE_NOT_RECRUITING